{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:02:55Z","timestamp":1790085775352,"version":"4.0.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The prognostic relevance of baseline low-level viremia (LLV) after hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) diagnosis remains uncertain. We evaluated the association between baseline LLV and overall survival (OS), explored related biological features, and developed survival prediction models for patients with baseline LLV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 921 patients with HBV-HCC: 611 with baseline LLV and 310 with HBV DNA &amp;lt;20 IU\/mL. Propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and Cox regression were used to assess the association between baseline HBV DNA status and OS. Peripheral T cell subsets and selected markers of hepatic functional reserve, hepatocellular injury, and systemic inflammation were explored. Patients with baseline LLV were randomly divided into training and reserved internal validation sets. Model 1 used the full candidate variable set, whereas Model 2 used non-imaging variables. Predictors were selected using LASSO Cox regression and Boruta, and five survival algorithms were compared within the training set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline LLV was associated with poorer OS. After PSM, HBV DNA &amp;lt;20 IU\/mL was associated with lower adjusted mortality than LLV (hazard ratio, 0.688; 95% confidence interval, 0.543\u20130.872; P = 0.002), with similar findings after IPTW. Patients with LLV had a lower peripheral CD4\/CD8 ratio, and exploratory analyses identified significant indirect associations through albumin, aspartate aminotransferase, and systemic immune-inflammation response index. Model 1 retained tumor size, tumor multiplicity, portal vein tumor thrombus, cholinesterase, alkaline phosphatase, and alpha-fetoprotein; Model 2 retained gamma-glutamyl transferase, cholinesterase, alkaline phosphatase, and alpha-fetoprotein. Random survival forest was selected based on overall training performance. In the reserved validation set, the 1-, 3-, and 5-year time-dependent AUCs were 0.824, 0.777, and 0.765 for Model 1 and 0.769, 0.742, and 0.723 for Model 2, respectively. Both models showed good calibration and positive net benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Baseline LLV remained prognostically relevant after HCC diagnosis and was accompanied by exploratory differences in systemic inflammation and the relative balance of peripheral T cell subsets. These findings support closer virological monitoring and individualized risk assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1900644","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:23:52Z","timestamp":1790083432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline low-level viremia in HBV-related hepatocellular carcinoma: prognostic significance, risk stratification, and clinical implications"],"prefix":"10.3389","volume":"17","author":[{"given":"Heng","family":"Ma","sequence":"first","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Yu","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Yan","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xie","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Shang","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyuan","family":"Huo","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxin","family":"Shi","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.01.033","article-title":"Global epidemiology and genetics of hepatocellular carcinoma","volume":"164","author":"Toh","year":"2023","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"B4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2025.1663858","article-title":"Unveiling low level viremia in chronic hepatitis B: Challenges and new horizons","volume":"15","author":"Wang","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001793","article-title":"Low-level viremia in nucleoside analog-treated chronic hepatitis B patients","volume":"134","author":"Zhang","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106334","article-title":"Low-level viremia increases the risk of adverse long-term outcomes in entecavir-treated patients with chronic hepatitis B","volume":"246","author":"Ji","year":"2026","journal-title":"Antiviral Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002181","article-title":"Low level of hepatitis B viremia compared with undetectable viremia increases the risk of hepatocellular carcinoma in patients with untreated compensated cirrhosis","volume":"118","author":"Yang","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/microorganisms12050976","article-title":"The effect of low HBV-DNA viral load on recurrence in hepatocellular carcinoma patients who underwent primary locoregional treatment and the development of a nomogram prediction model","volume":"12","author":"Xiong","year":"2024","journal-title":"Microorganisms"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70066","article-title":"Low-level viremia impairs efficacy of immune checkpoint inhibitors in unresectable hepatocellular carcinoma","volume":"45","author":"Li","year":"2025","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/17588359261435330","article-title":"Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: A multicenter retrospective study","volume":"18","author":"Lei","year":"2026","journal-title":"Ther Adv Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14750","article-title":"Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia","volume":"34","author":"Kim","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i11.1321","article-title":"Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients","volume":"16","author":"Lin","year":"2024","journal-title":"World J Hepatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","author":"Sun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29348","article-title":"Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages","volume":"66","author":"Cheng","year":"2017","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/liv.12112","article-title":"Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma","volume":"33","author":"Lao","year":"2013","journal-title":"Liver Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1464728","article-title":"Heterogeneity in peripheral blood immune lymphocyte subsets predicts the response of immunotherapy or chemoradiotherapy in advanced lung cancer: An analysis across different pathological types, treatment modalities and age","volume":"15","author":"Miao","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.4257","article-title":"Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria","volume":"151","author":"Lei","year":"2016","journal-title":"JAMA Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.10.17676","article-title":"Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: Chemoembolization and stent combined with iodine-125 seed","volume":"12","author":"Chuan-Xing","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41421-023-00563-x","article-title":"Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma","volume":"9","author":"He","year":"2023","journal-title":"Cell Discov"},{"key":"B34","doi-asserted-by":"publisher","first-page":"BSR20181058","DOI":"10.1042\/bsr20181058","article-title":"The prognostic significance of pretreatment serum \u03b3-glutamyltranspeptidase in primary liver cancer: A meta-analysis and systematic review","volume":"38","author":"Ou","year":"2018","journal-title":"Biosci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i31.10944","article-title":"Model based on \u03b3-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis","volume":"20","author":"Xu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/hc9.0000000000000879","article-title":"Low serum pseudocholinesterase levels are associated with mortality in patients with hepatocellular carcinoma","volume":"10","author":"Sato-Espinoza","year":"2026","journal-title":"Hepatol Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01827-24","article-title":"Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: A real-world 48-week extension study","volume":"69","author":"He","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2026.100629","article-title":"Maintaining versus switching antiviral therapy in chronic hepatitis B patients with low-level viremia","volume":"12","author":"Wang","year":"2026","journal-title":"J Virus Erad"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103400","article-title":"Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: A randomized, double-blind, placebo-controlled, multicenter phase II study","volume":"87","author":"Wang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:23:53Z","timestamp":1790083433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1900644"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900644","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1900644"}}